Type I collagen

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

Retrieved on: 
Thursday, June 29, 2023
Maintenance, CELU, COL1A1, Type I collagen, Therapy, B cell, CTM, Disability, Pathology, Instituto de Biologia Molecular e Celular, MMP1, Research, Pain, Tendon cell, Regeneration, SCX, Rupture, International Conference on Information Systems Security and Privacy, COL3A1, Patient, Extracellular matrix, CXCL8, TNC, Collagen, type III, alpha 1, Phenotype, III, Conference, Logging, Vaccine, Orthopedic surgery

FLORHAM PARK, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company will present data from a new product technology in development for orthopedic applications at the upcoming 7th International Conference on Orthopedics, July 19th – 20th in Rome.

Key Points: 
  • FLORHAM PARK, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company will present data from a new product technology in development for orthopedic applications at the upcoming 7th International Conference on Orthopedics, July 19th – 20th in Rome.
  • As a result, the healed tendon often is mechanically incompetent and prone to degeneration and rupture.
  • “Celularity leverages a diversified portfolio of therapeutic technologies all derived from a single source material — the post-partum placenta.
  • These early tenocyte data are an important demonstration of our ongoing commitment and focus on innovation leveraging the placental platform we have pioneered.”

ESSENT BIOLOGICS LAUNCHES MICRONIZED BONE MATRIX FOR 3D BIOPRINTING AND TISSUE ENGINEERING APPLICATIONS

Retrieved on: 
Tuesday, December 13, 2022
Spectral, Biotechnology, Research and development, MBM, Mineral, Regenerative medicine, Type I collagen, Bone, Particle size, Protein, Calcium, ECM, Good manufacturing practice, Osteon, Research, Element, 3D printing, 3D, Phosphorus, 3D bioprinting, Multimedia, Safety, Engineering, Collagen, CGMP, Silk, Medical imaging

CENTENNIAL, Colo., Dec. 13, 2022 /PRNewswire/ -- Essent Biologics, a leading supplier of human-derived cell and scaffold materials, today announced availability of its Micronized Bone Matrix (MBM) for 3D bioprinting and tissue engineering applications.

Key Points: 
  • CENTENNIAL, Colo., Dec. 13, 2022 /PRNewswire/ -- Essent Biologics, a leading supplier of human-derived cell and scaffold materials, today announced availability of its Micronized Bone Matrix (MBM) for 3D bioprinting and tissue engineering applications.
  • Essent Biologics will provide a mineralized allograft bone matrix derived from human ground cortical bone that contains native proteins, such as Collagen Type I, and native elements and minerals, such as calcium and phosphorus.
  • As an integral part of bone tissue engineering, scaffolds are 3D biocompatible structures which can mimic the ECM propertiesincluding mechanical support and cellular stimulation throughbiochemicaland mechanical interactionsand provide a template for cell attachment to stimulatebone tissue formation.
  • "Essent's MBM, along with our previously launched demineralized ground bone product, Spectral DBM, will support the work of those interested in human bone characterization as well as the burgeoning field of bone tissue engineering."

Orpheus Skin Launches A New Bioactive Micro-Foaming Resurrection Serum Slip Cleanser

Retrieved on: 
Thursday, October 20, 2022
Cream, Skin, CELL, Growth, MSRP, THE, Biotechnology, Research, Instagram, SKIN, Antioxidant, Inflammation, Technology, Collection, NEW, Serum, Lactic acid, Glass, Founder, Hyaluronic acid, Orpheus, Amazon, Environment, DNA, Type I collagen, Elastin, Lipid, Magic, Damask, ORPHEUS, Cosmetics, Sulfur

NEW YORK, Oct. 20, 2022 /PRNewswire-PRWeb/ -- ORPHEUS SKIN, the award-winning Bioactive skincare from Bulgaria known for their proprietary Youth-Restoring ORPHEUS Flower Cell Peptide Complex® and non-toxic, bioengineered formulas, has officially completed their skincare portfolio with the launch of the new bioactive amino acid micro-foaming Resurrection Serum Slip Cleanser – an innovative serum-to-foam formula packed with biominerals, antioxidants and adaptogens. The cleanser joins the brand's award-winning Resurrection Collection which includes a toner, essence, serum, and moisturizer. The cleanser will be available on Orpheus-skin.com and Amazon as of today, October 20, 2022 and will retail for $48 MSRP.

Key Points: 
  • NEW YORK, Oct. 20, 2022 /PRNewswire-PRWeb/ -- ORPHEUS SKIN, the award-winning Bioactive skincare from Bulgaria known for their proprietary Youth-Restoring ORPHEUS Flower Cell Peptide Complex and non-toxic, bioengineered formulas, has officially completed their skincare portfolio with the launch of the new bioactive amino acid micro-foaming Resurrection Serum Slip Cleanser an innovative serum-to-foam formula packed with biominerals, antioxidants and adaptogens.
  • The cleanser joins the brand's award-winning Resurrection Collection which includes a toner, essence, serum, and moisturizer.
  • To find out more information on the cleanser and ORPHEUS SKIN, visit the website or follow @Orpheus.Skin on Instagram.
  • ABOUT THE ORPHEUS SKIN RESURRECTION COLLECTION:
    ORPHEUS Resurrection All-In-One Serum ($130) - A radiance-boosting and collagen-building ancient botanical stem-cell concentrate that transforms the overall complexion and texture of even the most tired and stressed skin.

Neoss, Inc. is celebrating the launch of NeoGenix XP™

Retrieved on: 
Monday, October 25, 2021
Research, Patient, Osteocalcin, Prosthodontics, Type I collagen, Extracellular matrix, Cell adhesion, Multimedia, Membrane, Phosphorus

WOODLAND HILLS, Calif., Oct. 25, 2021 /PRNewswire/ -- Following thesuccessful and well-received Allograft line,Neoss is excited to announce the addition of NeoGenix XP this autumn to our existing product portfolio.

Key Points: 
  • WOODLAND HILLS, Calif., Oct. 25, 2021 /PRNewswire/ -- Following thesuccessful and well-received Allograft line,Neoss is excited to announce the addition of NeoGenix XP this autumn to our existing product portfolio.
  • NeoGenix XP is a safe and clinically proven natural bone substitute, that closer resembles natural bone than those of synthetic materials, such as hydroxyapatite or tricalcium phosphate.
  • "Being a strong partner to our customers has always been important and offering more in terms of total package solutions.
  • NeoGenix XP is an important addition to this and strengthens not only the bone regeneration portfolio but will allow us to serve our customer even better!"

The Ingredient Transparency Center's Collagen Stewardship Alliance Adds BioCell Technology to its Supporter List

Retrieved on: 
Thursday, July 15, 2021
Dietary Supplements, Branches of biology, Structural proteins, Collagens, Nutrition, Cell biology, Chondroitin sulfate, Gelatin, Type II collagen, Type I collagen

SPRING, Texas, July 15, 2021 /PRNewswire/ --Today, the Ingredient Transparency Center's Collagen Stewardship Alliance (CSA) announced that BioCell Technology, LLC has signed on as a Sponsor Level supporter.

Key Points: 
  • SPRING, Texas, July 15, 2021 /PRNewswire/ --Today, the Ingredient Transparency Center's Collagen Stewardship Alliance (CSA) announced that BioCell Technology, LLC has signed on as a Sponsor Level supporter.
  • BioCell Collagen is a clinically studied dietary supplement ingredient comprised of a complex matrix of primarily collagen type II peptides, chondroitin sulfate and hyaluronic acid.
  • "BioCell's values surrounding attribution of science and commitment to the collagen category align closely with CSA's and we're pleased to add them to our supporter roster," said Len Monheit, CEO, Trust Transparency Center and management lead for the Collagen Stewardship Alliance.
  • BioCell Collagen is a clinically studied dietary ingredient composed of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate, hyaluronic acid.

Eric Giza, MD, FACS Joins Alafair Biosciences Scientific & Clinical Advisory Board

Retrieved on: 
Wednesday, June 23, 2021
Anatomy, Skeletal system, Soft tissue, Branches of biology, Ankle, Foot, Tendon, Type I collagen, Orthopedic surgery, Ligament

AUSTIN, Texas, June 23, 2021 /PRNewswire/ --Medical device innovator Alafair Biosciences announces the appointment of Eric Giza, MD, FAAOS to its Scientific & Clinical Advisory Board.

Key Points: 
  • AUSTIN, Texas, June 23, 2021 /PRNewswire/ --Medical device innovator Alafair Biosciences announces the appointment of Eric Giza, MD, FAAOS to its Scientific & Clinical Advisory Board.
  • Dr. Giza is UC Davis' Chief of Orthopaedic Foot & Ankle Surgery and Co-director of the Foot & Ankle Fellowship.
  • Alafair offers VersaWrap, an ultrathin, HA-based, non-collagen implant that protects peripheral nerves, tendons, and surrounding tissues such as ligaments and skeletal muscles.
  • Alafair Biosciences announces the appointment of Eric Giza, MD, FAAOS to its Scientific & Clinical Advisory Board.

Worldwide Medical Collagen Industry to 2028 - by Source, Product, Application and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, May 24, 2021
Biotechnology, Health, Surgery, Structural proteins, Collagen, Compound annual growth rate, Type I collagen, Branches of biology

The "Medical Collagen Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source, Product, and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Collagen Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Source, Product, and Application" report has been added to ResearchAndMarkets.com's offering.
  • The medical collagen market is expected to reach 957.4 million by 2028 from US$ 593.7 million in 2020; it is estimated to grow at a CAGR of 6.2% from 2021 to 2028.
  • The growth of the market is mainly attributed to the rising applications of collagen in the medical industry, and increasing number of FDA approvals and product launches.
  • Constant advancements in products and the approvals of medical collagen products are further driving the growth of the medical collagen market.

New Skin Care Line, Orora, Launches Products with the First Bioidentical Human Collagen Ingredient in North America

Retrieved on: 
Wednesday, May 19, 2021
Articles, Structural proteins, Medicine, Branches of biology, Collagen, Veganism, Bioidentical hormone replacement therapy, Type I collagen

a holistic beauty brand dedicated to bringing the most unique and effective ingredients to skincare, launched two products with the first vegan bioidentical human collagen ingredient in North America.\nThe products are formulated with Geltor\'s bioactive human collagen ingredient, HumaColl21, a biodesigned peptide (INCI: sh-polypeptide-121)that works to stimulate the skin\'s natural collagen synthesis.

Key Points: 
  • a holistic beauty brand dedicated to bringing the most unique and effective ingredients to skincare, launched two products with the first vegan bioidentical human collagen ingredient in North America.\nThe products are formulated with Geltor\'s bioactive human collagen ingredient, HumaColl21, a biodesigned peptide (INCI: sh-polypeptide-121)that works to stimulate the skin\'s natural collagen synthesis.
  • "Featuring the firstbioidentical human collagen ingredient and the proven effectiveness of HumaColl21 in beauty products is going to change the way customers experience skincare.
  • Orora partners with cutting-edge science to make the latest innovations accessible for those seeking the next frontier of beauty.
  • Orora launched in 2021 with a product line formulated with the first bioidentical and vegan collagen ingredient in a skincare product line in North America.

Marine Collagen Market worth $1,137 million by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, April 2, 2021
Collagens, Structural proteins, Type I collagen, Branches of biology

The Type I marine collagen segment, by type, is projected to witness stalwart growth during the forecast period.

Key Points: 
  • The Type I marine collagen segment, by type, is projected to witness stalwart growth during the forecast period.
  • As a result, the market for type I marine collagen is presenting a host of opportunities that will help propel the marine collagen market.
  • Busy lifestyles and increasing cases of chronic diseases like diabetes and obesity are fueling the demand for marine collagen as a nutraceutical ingredient, and thus this segment is experiencing significant growth in the marine collagen market.
  • Asia Pacific is projected to hold the largest share in the marine collagen market.

Marine Collagen Market worth $1,137 million by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Friday, April 2, 2021
Collagens, Structural proteins, Type I collagen, Branches of biology

The Type I marine collagen segment, by type, is projected to witness stalwart growth during the forecast period.

Key Points: 
  • The Type I marine collagen segment, by type, is projected to witness stalwart growth during the forecast period.
  • As a result, the market for type I marine collagen is presenting a host of opportunities that will help propel the marine collagen market.
  • Busy lifestyles and increasing cases of chronic diseases like diabetes and obesity are fueling the demand for marine collagen as a nutraceutical ingredient, and thus this segment is experiencing significant growth in the marine collagen market.
  • Asia Pacific is projected to hold the largest share in the marine collagen market.